Pharmacokinetic and pharmacodynamic analysis of platinum after combined treatment of cisplatin and procainamide hydrochloride in mice bearing P388 leukemia

Anticancer Research

Volumn 23, Issue 2 B, 2003, Pages 1509-1516

  Vannozzi, Maria O ^a   Ottone, Massimo ^a   Mariggiò, Maria A ^b   Cafaggi, Sergio ^c   Parodi, Brunella ^b   Cilli, Michele ^a   Lindup, Edward ^d   Viale, Maurizio ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Ospedale Consorziale Policlinico   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Cisplatin; Pharmacokinetics and pharmacodynamics; Procainamide hydrochloride

Indexed keywords

CISPLATIN; PROCAINAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; ASCITES FLUID; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DNA BINDING; DRUG RESEARCH; FEMALE; IN VIVO STUDY; KIDNEY; LIVER; LUNG; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; SPLEEN; TISSUE BLOOD FLOW;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; ASCITIC FLUID; CISPLATIN; CROSS-LINKING REAGENTS; DNA ADDUCTS; DNA, NEOPLASM; FEMALE; HEPATITIS, TOXIC; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; KIDNEY DISEASES; LEUKEMIA P388; MICE; ORGAN SPECIFICITY; PLATINUM; PROCAINAMIDE; TISSUE DISTRIBUTION;

EID: 0037900643     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Thigpen T, Vance R, Puneky L and Khansurt T: Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol 55: 597-607, 1994.
2. Van Basten JP, Schrafford-Koops H, Sleijfer DT, Pras E, van Driel M F and Hoekstra HJ: Current concept about testicular cancer. Eur J Surg Oncol 23: 354-360, 1997.
3. Recchia F, Lalli A, Lombardo M, De Filippis S, Saggio G, Fabbri F, Rosselli M, Capomolla E and Rea S: Ifosfamide, cisplatin, and 13-cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I-II study. Cancer 92: 814-821, 2001.
4. Screnci D and McKeage MJ: Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J Inorg Biochem 77: 105-10, 1999.
5. Mollman JE, Glover DJ, Hogan WM and Furman RE: Cisplatin neuropathy risk factors, prognosis and protection by WR-2721. Cancer 61: 2192-2195, 1988.
6. Sweeney C: History of testicular cancer chemotherapy: maximizing efficacy, minimizing toxicity. Semin Urol Oncol 19: 170-179, 2001.
7. Pinzani V, Bressolle F, Haug IJ, Galtier M, Blayac JP and Balmès P: Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 35: 1-9, 1994.
8. Skinner R: Strategies to prevent nephrotoxicity of anticancer drugs. Curr Opin Oncol 7: 310-315, 1995.
9. Markman M: Amifostine in reducing cisplatin toxicity. Semin Oncol 25: 522-524, 1998.
10. Esposito M, Viale M, Vannozzi MO, Zicca A, Cadoni A, Merlo F and Gogioso L: Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diamminedichloroplatinum(II). Toxicol Appl Pharmacol 140: 370-377, 1996.
11. Viale M, Vannozzi MO, Pastrone I, Mariggiò MA, Zicca A, Cadoni A, Cafaggi S, Tolino G, Lunardi G, Civalleri D, Lindup WE and Esposito M: Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role? J Pharmacol Exp Toxicol 293: 829-836, 2000.
12. Zicca A, Cafaggi S, Mariggiò MA, Vannozzi MO, Ottone M, Bocchini V, Caviglioli G and Viale M: Reduction of cisplatin hepatotoxicity by procainamide hydrochloride in rats. Eur J Pharmacol 442: 265-272, 2002.
13. Gao X, Fernandez-Vina M, Shumwa W and Stastny P: DNA typing for class II HLA antigens with allele-specific or group-specific amplification. I. Typing for subsets of HLA-DR4. Hum Immunol 27: 40-50, 1990.
14. Coluccia M, Boccarelli A, Mariggiò MA, Cardellicchio N, Caputo P, Intini FP and Natile G: Platinum(II) complexes containing iminoethers: a trans platinum antitumor agent. Chem Biol Interact 98: 251-266, 1995.
15. Fulco RA, Vannozzi M, Collecchi P, Merlo F, Parodi B, Civalleri D and Esposito M: Effect of normal saline on cisplatin pharmacokinetics and antitumor activity in mice bearing P388 leukemia. Anticancer Res 10: 1603-1610, 1990.
16. Pera MF Jr and Harder HC: Analysis for platinum in biological material by flameless atomic absorption spectrometry. Clin Chem 23: 1245-1249, 1977.
17. Oldfield EH, Clark WC and Dedrick RL: Reduced systemic drug exposure by combining intraarterial cis-diamminedichloro-platinum(II) with hemodialysis of regional venous drainage. Cancer Res 47: 1962-1967, 1987.
18. Esposito M, Vannozzi MO, Viale M, Pellecchia C, Merlo F, Cadoni A, Cafaggi S, Parodi B, Lerza R and Poirier MC: Cis-diamminedichloroplatinum(II)-procaine pharmacokinetic interaction in mice bearing P388 leukemia. Anticancer Res 13: 1511-1516, 1993.
19. Esposito M, Viale M, Vannozzi MO and De Cian F: Modulation of the therapeutic efficacy of cisplatin in rats using procainamide. Tumori (Suppl.) 81: 135 [Abstrtact 413], 1995.
20. Reece PA, Stafford I, Russel J, Khan M and Gill PG: Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 5: 304-309, 1987.
21. Powis G: Anticancer drug pharmacodynamics. Cancer Chemother Pharmacol 14: 177-183, 1985.
22. Ali-Osman F, Berger MS, Rajagopal S, Spence A and Livingston RB: Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand crosslinks and cytotoxicity in human glioblastoma cells. Cancer Res 53: 5663-5668, 1993.
23. Roberts JJ and Friedlos F: Quantitative estimation of cisplatin-induced DNA interstrand cross-links and their repair in mammalian cells: relationship to toxicity. Pharmacol Ther 34: 215-246, 1987.
24. Petersen LN, Mamenta EL, Stevnsnet, Chaney SG and Bohr VA: Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity. Carcinogenesis 17: 2597-2602, 1996.
25. Johnson SW, Swiggard PA, Handel LM, Brennan JM, Godwin AK, Ozols RF and Hamilton TC: Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res 54: 5911-5916, 1994.
26. Cafaggi S, Esposito M, Parodi B, Vannozzi MO, Viale M, Pellecchia C, Fulco RA, Merlo F, Zicca A, Cadoni A and Bignardi G: Synthesis and antitumor activity of a new cis-diammineplatinum(II) complex containing procaine hydrochloride. Anticancer Res 12: 2285-2292, 1992.
27. Zhang JG, Esposito M, Cafaggi S and Lindup WE: Comparison of the toxicities of cisplatin and a new cisplatin-procaine complex to rat renal cortical slices. Hum Exp Toxicol 15: 59-63, 1996.
28. Mandys V, Viale M, Vrana J, Cafaggi S and Esposito M: Neurotoxic effect of cisplatin and the cisplatin-procaine complex DPR studied in organotypic cultures of chick embryonic dorsal root ganglia. Anticancer Res 9: 659-663, 1998.
29. Viale M, Cafaggi S, Parodi B and Esposito M: Cytotoxicity and cellular accumulation of a new cis-diammineplatinum(II) complex containing procaine in murine L1210 cells sensitive and resistant to cis-diamminedichloroplatinum(II). Cancer Chemother Pharmacol 35: 371-376, 1995.
30. Natochin YuV, Reznik LV, Bakhteeva EM and Broutsyn VK: Cisplatin nephrotoxic action in vertebrates and its prevention. Comp Biochem Physiol 94c: 115-120, 1989.
31. Basinger MA, Jones MM and Holscher MA: L-Methionine antagonism of cis-platinum nephrotoxicity. Toxicol Appl Pharmacol 103: 1-15, 1990.
32. Hanigan MH, Gallagher BC and Taylor PT Jr: Cisplatin nephrotoxicity inhibition of gamma-glutamyl transpeptidase blocks the nephrotoxicity of cisplatin without reducing platinum concentrations in the kidneys. Am J Obstet Gynecol 175: 270-273, 1996.
33. Meijer DK, Mol WE, Müller M and Kurz G: Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations. J Pharmacokinet Biopharm 18: 35-70, 1990.
34. Pritchard JB and Miller DS: Renal secretion of organic anions and cations. Kidney Int 49: 1949-1954, 1996.